The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Items 601–700 of 798
Kaur, G., Wang, Q., Tjitropranoto, A., Unwalla, H. J., & Rahman, I. (2024) · Experimental Lung Research · doi:10.1080/01902148.2024.2414974 · Cited by 1
“29 However, according to the 2012 report by United Network for Organ Sharing, only 21% of donor lungs are deemed fit for transplant, while the rest are considered non-transplantable.”
Bertani, A., Tancredi, G., Monte, L. D., et al. (2024) · Organ and tissue transplantation · doi:10.1007/978-3-030-36123-5_12
Dealing with Difficult Bugs Before Lung Transplantation
Mehta, N., Lyon, G. M., & Pouch, S. M. (2024) · Organ and tissue transplantation · doi:10.1007/978-3-030-36123-5_16
Liu, T., Zhang, Y., Yang, H., et al. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.10.069
Prada, G., Daubenspeck, D. K., Chan, E. G., Sánchez, P. G., & Martin, A. K. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.11.023
Heart and lung transplantation
Doi, A., Marasco, S., Patel, H. C., Paraskeva, M. A., & McGiffin, D. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22148-4.00002-2
(2000) · Time to knit · doi:10.1016/s1155-195x(23)92212-7
Revisión actualizada de enfermedades pulmonares intersticiales en enfermedades autoinmunes
López, D. I., & Tobón, G. B. Z. (2025) · Medicina e Investigación Universidad Autónoma del Estado de México · doi:10.36677/medicinainvestigacion.v13i1.24616
Concha, S. T., Fariñas-Álvarez, C., Muñoz, P., Martínez, J. M. C., Gil, J. Z., & Blanco, J. A. P. (2025) · Tomography · doi:10.3390/tomography11020011
“Despite these advances, CAD remains a relative contraindication for lung transplantation [9], and for this reason, many centers include CA in the pre-transplant protocol for patients over 40 to 45 years of age [10,11].”
Levêque, M., Bermudez, J., Nieves, A., et al. (2025) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2025.101158
Wong, M., Gardiner, B. J., Stirling, R. G., Adabi, G., Riley, B., Prasad, J. D., & Snell, G. I. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.52597
Basza, M., Bojanowicz, W., Galle, D., et al. (2025) · doi:10.2196/preprints.72024
Lee, S. Y., Lee, H. N., Koo, H. J., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.02.1576
Bitterman, R., Soualhine, H., Akochy, P., Poirier, C. D., Ferraro, P., Kabbani, D., Hirji, A. S., Tyrrell, G. J., Bergeron, C., Levy, R. D., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70003
“A recent expert-based Delphi panel recommended to achieve AFB smear negativity before LT, but that achieving culture negativity may not be required [10].”
Maligireddy, A. R., Jabri, A., Rojulpote, C., et al. (2025) · Annals of Thoracic Surgery Short Reports · doi:10.1016/j.atssr.2025.01.022
Laothamatas, K., Benvenuto, L. J., Raval, M., et al. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2025.02.020
Self-citationThe Role of Pulmonary Rehabilitation in Lung Transplantation for Cystic Fibrosis
Pehlivan, E. (2025) · OBM Transplantation · doi:10.21926/obm.transplant.2501239
Tam, P. C. K., Messina, J. A., Ni, B., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100238
“19 In this study, 8 PWH underwent thoracic organ transplant with organs from donors without HIV, demonstrating good medium-term clinical outcomes.”
Varón-Vega, F. A., Téllez, L. J., Tuta-Quintero, E., Rincón, A., Casas, D., Rodríguez, C., Mendoza, D., & Giraldo‐Cadavid, L. F. (2025) · Canadian Respiratory Journal · doi:10.1155/carj/1861990
“Te evaluation and selection process for transplantation must minimize perioperative risks and positively impact posttransplant survival [2, 3].”
Azam, A., Barry, P. J., Bright-Thomas, R. J., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108086
Gade, N., Seifert, P., Gerckens, M., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70157
Lung Transplantation Outcomes in Candidates Aged ≥ 70 Years Old: A 10-Year Single Center Experience
Aubrey, J. M., Thorp, S., Lawson, C., Pokora, I., Weissman, C. R., Pamidighantam, P., Zimmer, T., Chen, C., Chicotka, S. R., Girgis, R. E., et al. (2025) · JHLT Open · doi:10.1016/j.healun.2025.02.396
Timing of lung transplant evaluation: considerations, barriers and alternatives
van der Ploeg, E. A., Hylkema, T. H., & Gan, C. T. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001176
Huang, J. H., Friedman‐Moraco, R., & Pouch, S. M. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001177
YUEN, A. D., Zaffiri, L., Tapson, V. F., et al. (2025) · Respiratory Care · doi:10.1089/respcare.12900
Chen, L., Wang, J., Jin, C., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07315-x
“Meanwhile, poor pulmonary function is often accompanied with worse cardiac function [ 24], which could lead to increased risk of adverse outcome after LTx [ 7].”
Infections in Pediatric Lung Transplantation
Green, A. M., & Danziger‐Isakov, L. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00073-x
Izhakian, S., Gagula, M., Engelstein, H., Malka, L., Freidkin, L., Rosengarten, D., & Kramer, M. R. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002614
Karampitsakos, Τ., Qureshi, M. R., Hammonds, J., Guzman, C. A., Albuquerque, R., Tourki, B., Fatima, Z., Henriquez, N., Calderon, V., Fadli, T., et al. (2025) · medRxiv · doi:10.1101/2025.05.26.25328338
Claeys, E., Crem, N. D., Mol, P. V., Vanstapel, A., Ceulemans, L. J., Raemdonck, D. E. V., Dooms, C., Wever, W. D., Deroose, C. M., Bempt, I. V., et al. (2025) · Case Reports in Oncology · doi:10.1159/000545190
“Currently, individuals with active lung cancer are excluded from consideration for LTx, especially because of a concern about cancer control under intense immunosuppression required for transplant maintenance [9].”
Cuesta, V. M. M., Meñaca, A. M., Fernandez, D. I., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70107
Lungentransplantation – verleiht mehr als Flügel
Aigner, C. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2603-9353
Vecchia, I. D., Andriotti, M. Z., Deponti, G. N., et al. (2025) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v28i1.685_eng
Vecchia, I. D., Andriotti, M. Z., Deponti, G. N., et al. (2025) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v28i1.685_port
An unprecedented pathology in a 20-year-old with progressive dyspnoea and parenchymal infiltrates
Al-Mukhaizeem, A., O’Reilly, K. M., Reddy, P., et al. (2025) · Breathe · doi:10.1183/20734735.0040-2025
Perez, A. A., & Leard, L. E. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.06.020
Self-citationDouble-Lung Transplant With Delayed Nuss Bar Prostheses for Pectus Excavatum Deformity
Alzahrani, A., Castro-Medina, M., Furukawa, M., et al. (2025) · Annals of Thoracic Surgery Short Reports · doi:10.1016/j.atssr.2025.06.005
The Technical Question Seems Solved, but the Allocation Question Has Not
Ellison, T. A. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.06.024
Ar, U., Kutukcu, E. C., & Sağlam, M. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2535760
“Lung transplant candidates frequently experience severely reduced 6-minute walk distance (6MWD) and diminished peak oxygen consumption (VO₂ peak), parameters that serve as prognostic indicators of mortality in this patient cohort [5].”
Lombardi, A., & Renisi, G. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70088
Fuller, L. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.07.038
Impact of donor-recipient ethnic matching on survival after lung transplantation in Italy
Palleschi, A., Schiavon, M., Besani, P., et al. (2025) · Updates in Surgery · doi:10.1007/s13304-025-02371-2
“Since lung transplantation is a lifesaving procedure, the principles of utility, justice and respect for persons should be respected and guaranteed [1].”
Catelli, C., Madrid, A. L., Bennett, D., d’Alessandro, M., Guerrieri, M., Rizzo, M., Marianello, D., Fossi, A., Paladini, P., Bargagli, E., et al. (2025) · Transplantology · doi:10.3390/transplantology6030028
Rinaldo, R. F., Curtoni, A., Verardo, M., Zaffina, S., Shbaklo, N., Sidoti, F., Rosa, F. G. D., Corcione, S., Boffini, M., Marro, M., et al. (2025) · Life · doi:10.3390/life15091462
“Lung transplantation has become an internationally acknowledged therapeutic approach for the management of end-stage pulmonary diseases, offering an expected improvement in the survival and quality of life of the recipients [1].”
The prognosis of lung transplant candidates with progressive pulmonary fibrosis
Yamaya, T., Muraoka, T., Yamaguchi, M., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.09.009
Lung transplantation for chronic obstructive pulmonary disease patients: an overview
Naamani, T. I., Verplancke, V., & Verleden, G. M. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001226
Şahin, M. F., Esendağlı, G., Yıldırım, F., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19711-2
History of Respiratory Medicine in Canada: Pulmonary hypertension
Mehta, S., Singh, N., Myrah, J., et al. (2025) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2025.2555848
Agarwal, S., Mohan, A., Rathi, V., Madan, K., Hadda, V., Mittal, S., Tiwari, P., Suri, T. M., Guleria, R., Hote, M. P., et al. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3342
Metabolisch bariatrische Operation als „Bridging“ zur Transplantation – Konzepte und Ergebnisse
Lange, U. G., & Dietrich, A. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02391-z
Bronchiectasis associated with ulcerative colitis relapse after lung transplantation: a case report
Nassurally, F., Pencreach, E., Hirschi, S., Vallat, L. D., Rimelen, V., Dégot, T., Furstenberger, M., Rahli, M., Kessler, R., Falcoz, P., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.01187-2025
“LTx has been established as a life-prolonging therapy for end-stage lung diseases [1].”
Ripoll, J. G., Esmailzadeh, S., Sanborn, D. M., Jackowski, T. P., Bittner, E. A., Chang, M. G., Ortoleva, J. P., Wieruszewski, P. M., Nabzdyk, C. S., Al-Ani, R. I., et al. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.10.038
Precision Medicine in Lung Transplantation
Kayalar, N., & Saddoughi, S. A. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.07.009
Goodman, J. R., Bankar, D., Rao, V. K., & Vogelsong, M. A. (2025) · ASAIO Journal · doi:10.1097/mat.0000000000002596
Pectus Excavatum Repair During Lung Transplantation in a 5-Year-Old: A Case Report
Schwab, M. E., Martin, E., Si, X., et al. (2025) · Interdisciplinary CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivaf263
Tóth, N. M., Kramer, M. R., Šterclová, M., Müller, V., Lewandowska, K. B., Moğulkoç, N., Hájková, M., Studnicka, M., Tekavec-Trkanjec, J., Dimić-Janjić, S., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112684
Lee, D., Choi, E.-J., Jang, J. H., Cho, W. H., & Yeo, H. J. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.10.017
Solidoro, P., Curtoni, A., Perotti, C. G., Perotti, C., Shbaklo, N., Sidoti, F., Mangiapia, M., Rosa, F. G. D., Corcione, S., Boffini, M., et al. (2025) · Pathogens · doi:10.3390/pathogens14111157
Lee, B. S., Melehani, J. H., Li, S., Mooney, J. J., & Chung, L. S. (2025) · ACR Open Rheumatology · doi:10.1002/acr2.70134
“19,20 However, little is known about the incidence, risk factors, and survival outcomes of patients with digital gangreneundergoingtransplantation.”
Lungentransplantation bei Kindern und Jugendlichen
Carlens, J., Schwerk, N., & Müller, C. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02306-6
Nair, P., Morgan, S., Jansz, P. C., & Plit, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00118-3
Ruigrok, D., Boersma, L. E., Admiraal, J., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100458
Rich, R. L., Peterson, A., & Brown, J. (2025) · AACN Advanced Critical Care · doi:10.4037/aacnacc2025847 · Cited by 2
Does donor age older or younger than 70 years influence lung transplantation outcomes?
Ögren, E., Magnusson, J. M., Tholén, M., Hansson, E. C., Pivodic, A., & Dellgren, G. (2025) · JTCVS Open · doi:10.1016/j.xjon.2025.101555
Self-citationElmadhoun, O., Teixeira, M. T., Saddoughi, S. A., Fritz, A. V., Abutaka, A., Qamar, Y., Nabzdyk, C. S., Combes, A., Yalamuri, S. M., & Ramakrishna, H. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.12.011
Marcha nórdica: herramienta de salud en la rehabilitación postrasplante pulmonar
Gómez-Garrido, A., Mayer-Frutos, A. I., Roca-Escrihuela, R., et al. (2025) · Rehabilitación · doi:10.1016/j.rh.2025.100954
Burdis, N., Kapnadak, S. G., Bartlett, L. E., McElvaney, O. J., Milinic, T., Wai, T. H., Lange, A. V., Reid, N., Dunitz, J. M., Billings, J. L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750891
Self-citationGholamzadeh, M., Abtahi, H., & Safdari, R. (2023) · Figshare · doi:10.6084/m9.figshare.22608622
Shelley, B., McAreavey, R., & McCall, P. (2024) · Figshare · doi:10.6084/m9.figshare.25698224
Nikkuni, E., Hirama, T., Ui, M., Watanabe, T., Mukai, S., Watanabe, T., Watanabe, Y., Oishi, H., Ebihara, S., & Okada, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26333334
Salvatori, M., & Huang, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-06112-6_3
The unsung heroes: A scoping review of the experiences of lung transplant informal caregivers
Simanovski, J., Ralph, J., Crawley, J., Bryce, K., Sleiman, D., & Cruz, E. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100472 · Cited by 1
YUEN, A. D., Barnes, D., Shitanishi, L., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70164
“Currently, HIV infection with an undetectable viral load (VL) is considered a risk factor for unfavorable short-and long-term outcomes after lung transplantation (LT), with an absolute CD4 + T cell count (aCD4) minimum of 200 cells per microliter being a commonly accepted cutoff for candidacy [ 4 ].”
Pulmonary Hypertension Complicating Interstitial Lung Disease: Current Concepts and Controversies
King, C. S., & Thomas, C. (2025) · Respiratory medicine · doi:10.1007/978-3-032-03581-3_9
Carolan, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-025-00452-z
“Absolute contraindications, such as a malignancy in the last 5 years [12 ] are also more common in the older population, making lung transplantation less likely.”
Cajas, L. J., Galindo, J. L., Gil, D. R., et al. (2026) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2025.504841
An international perspective on allocation rules for combined heart-lung transplantation
Holm, A. M., Bello, I., Sandiumenge, A., Snell, G., & Gottlieb, J. (2026) · JHLT Open · doi:10.1016/j.jhlto.2025.100475 · Cited by 1
Self-citationLung transplant evaluation—complications on a timeline
Wu, M. Y., & Ferreira, A. O. (2026) · Clinical Radiology · doi:10.1016/j.crad.2026.107250
Bone Health in Young Lung Transplant Recipients: A Retrospective Study
Lerman, A., Shtraichman, O., Rudman, Y., Kramer, M. R., Dotan, I., Tsvetov, G., & Diker‐Cohen, T. (2026) · Respiration · doi:10.1159/000550456
“Current candidate selection guidelines identify osteoporosis as a relevant risk factor for adverse posttransplant outcomes and suggest BMD assessment prior to transplant [18].”
Kidney allograft outcomes in combined kidney with other solid organ transplantation
Belal, A. A., Bourricaudy, R. A., Saba, Z., Alquadan, K. F., Kazory, A., & Santos, A. H., Jr. (2026) · World Journal of Transplantation · doi:10.5500/wjt.v16.i1.114233
Lung Transplantation and Reverse Potts Shunt for Pulmonary Hypertension in the Pediatric Population
Klouda, T. M., Wong, W., Fynn‐Thompson, F., Esch, J. J., Josephson, M. B., Krishnan, U., Mıdyat, L., & Mullen, M. P. (2026) · Pediatric Transplantation · doi:10.1111/petr.70263
“…RAP > 15 mm Hg, significant signs of worsening disease process such as progressive right heart dysfunction, pericardial effusion, hemoptysis, and other signs of worsening right heart failure including renal dysfunction, recurrent ascites, or rising levels of serum BNP or bilirubin [31, 36, 39].”
Asija, R., Halpern, S. E., Olverson, G., et al. (2026) · CHEST Critical Care · doi:10.1016/j.chstcc.2026.100234
Ramirez, J., Kamepalli, S., & Rana, A. A. (2026) · Clinical Transplantation · doi:10.1111/ctr.70454
Alsubaiei, M. E. (2026) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2025.12.009
The Critically Ill Lung Transplant Candidate: How Sick is too Sick?
Lerner, G. R., Gonzalez, E. L., & Salgado, J. C. (2026) · Current Transplantation Reports · doi:10.1007/s40472-026-00504-z
“Recent guidelines have embraced a more comprehensive approach that considers age in the context of an individual’s comorbidities, functional reserve, and frailty [6 , 7].”
Lung retransplantation after initial single lung transplantation
Theeuwen, H. A., RODMAN, J. C., Lester, L. A., Udelsman, B. V., Rosenberg, G. M., Wightman, S. C., Kim, A. W., Atay, S. M., & Harano, T. (2026) · JHLT Open · doi:10.1016/j.jhlto.2026.100508
Zhang, D., Du, W., Li, P., et al. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70153
Beyond Survival: Early Perceived Quality of Life Outcomes After Lung Transplantation
Saavedra-Villafruela, A., González-Najarro, E., Lamas-Fernández, F. J., de Llano-Conde, M. J. C., Padilla, E. M., & Vaquero-Barrios, J. M. (2026) · Transplantation Proceedings · doi:10.1016/j.transproceed.2026.01.013
Prigg, A., Smith, O. A., Lipkin, G. W., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110461
Zhu, Q., Tang, L., Lin, P., Zeng, F., & Lan, M. (2026) · BMC Nursing · doi:10.1186/s12912-026-04441-1 · Cited by 1
“Lung transplantation has become an important therapeutic option for end-stage lung disease [1].”
Jones, T. E., Franklin, M., Oli, M., Walker, K., Bobba, C. M., Vasilopoulos, T., Younis, M., Emtiazjoo, A. M., Pipkin, M., Račkauskas, M., et al. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.02.019
Psychosocial challenges with transplantation
Primera, G., Anderson, M. R., & Koons, B. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001256
Truth vs Test: The Value of Cotinine in Lung Transplant Candidates Assessment
Zuazaga‐Fuentes, J., Cuesta, V. M. M., Fernandez, D. I., et al. (2026) · Transplantation Proceedings · doi:10.1016/j.transproceed.2026.02.021
How to Care for the Patient With Methamphetamine-Associated Pulmonary Arterial Hypertension
Kolaitis, N. A., Barnett, C., Chin, K., Clapham, K. R., Incze, M. A., Kennedy, A. J., Kingrey, J. F., Matusov, Y., Melendres-Groves, L. D., Rischard, F. P., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.02.016
Self-citationPrediction models for primary graft dysfunction after lung transplantation: Systematic review
Zhao, R., Bu, X., & fan, R. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101017
Ding, Q., Sun, T., Zhang, Z., et al. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14235-5
“For patients with end-stage COPD, lung transplantation (LT) emerges as a potentially life-extending therapeutic option, offering improved quality of life and functional status [3, 4].”
Idiopathic interstitial lung diseases - treatment options
Šterclová, M. (2026) · Česká a slovenská farmacie · doi:10.36290/csf.2026.003
Banga, A., Valentine, V. G., Rao, V. K., Kappalayil, A. P., Guenthart, B. A., MacArthur, J. W., & Dhillon, G. S. (2026) · Transplantation Direct · doi:10.1097/txd.0000000000001918
“13,14 Simultaneously, there are aggressive efforts to expand the donor pool through greater utilization of extended criteria donors (ECDs) 15,16 and donation after circulatory death (DCD) donors, 17,18 longer ischemic times, 19 and the use of machine perfusion for lung reconditioning.”
Anellovirus-mediated interferon dysregulation enhances virus-induced lung injury
Banday, M. M., Banday, S., Rahman, M. M., Harrison, A. O., Singh, N., Moore, R. M., Khan, M. M., Shankar, S., Goda, Y., Coppolino, A., et al. (2026) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1093/ajrcmb/aanag048
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
